Fueled, in part, by the Capsugel acquisition, Lonza posted good gains in the first half and raised expectations for the full year. Organic sales increased 8.2% during the period to CHF3.1 billion. One year after the successful closing of the Capsugel acquisition, sales amounted to CHF 3.1 billion ($3.1 billion) for the half-year 2018; and margins for Lonza further improved, resulting in a CORE EBITDA margin of 26% and a CORE EBIT margin of 20.3%. All figures are in reported currency and compared...